Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Eli Lilly & Co.’s stock soared 14% Thursday ... stage trial of a GLP-1 treatment for Type 2 diabetes and obesity in pill form. The last time the stock rose as much was June 29, 2000, when ...